Skip to main content

Table 3 The global market size for molecular diagnostics blood cancer diagnoses (Unit: million $) [7]

From: The market trend analysis and prospects of cancer molecular diagnostics kits

Category / Year

2013

2014

2015

2016

2017

2018

2019

CAGR

RT-PCR

Leukemia

35.7

37.6

47.6

60.3

76.4

96.7

122.5

26.6%

Lymphoma

5.8

6.8

10.9

17.3

27.6

44.1

70.4

59.6%

Sub-total

41.5

44.4

58.5

77.6

104.0

140.8

192.9

34.1%

DNA microarray

Leukemia

20.8

22.0

28.8

37.7

49.3

64.5

84.4

30.9%

Lymphoma

10.2

11.9

20.5

35.3

60.7

104.5

179.8

72.1%

Sub-total

31.0

33.9

49.3

73.0

110.0

169.0

264.2

50.8%

LOAC

Leukemia

3.0

3.2

4.1

5.2

6.7

8.5

10.9

27.8%

Lymphoma

 

Sub-total

3.0

3.2

4.1

5.2

6.7

8.5

10.9

27.8%

NGS

Leukemia

15.0

25.5

44.3

76.9

133.5

231.7

402.3

73.6%

Lymphoma

13.8

17.8

34.2

65.9

126.8

244.0

469.4

92.4%

Sub-total

28.8

43.3

78.5

142.8

260.3

475.7

871.7

82.3%

Multiplex conventional

Leukemia

 

Lymphoma

13.1

15.4

24.0

37.3

58.1

90.4

140.8

55.7%

Sub-total

13.1

15.4

24.0

37.3

58.1

90.4

140.8

55.7%

Blood cancer total

117.4

140.2

214.4

335.9

539.1

884.4

1480.5

60.2%